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Abstract In 1993, Przyklenk and colleagues made the
intriguing experimental observation that ‘brief ischemia in
one vascular bed also protects remote, virgin myocardium
from subsequent sustained coronary artery occlusion’ and
that this effect ‘…. may be mediated by factor(s) activated,
produced, or transported throughout the heart during brief
ischemia/reperfusion’. This seminal study laid the foun-
dation for the discovery of ‘remote ischemic conditioning’
(RIC), a phenomenon in which the heart is protected from
the detrimental effects of acute ischemia/reperfusion injury
(IRI), by applying cycles of brief ischemia and reperfusion
to an organ or tissue remote from the heart. The concept of
RIC quickly evolved to extend beyond the heart, encom-
passing inter-organ protection against acute IRI. The cru-
cial discovery that the protective RIC stimulus could be
applied non-invasively, by simply inflating and deflating a
blood pressure cuff placed on the upper arm to induce
cycles of brief ischemia and reperfusion, has facilitated the
translation of RIC into the clinical setting. Despite inten-
sive investigation over the last 20 years, the underlying
mechanisms continue to elude researchers. In the 8th
Biennial Hatter Cardiovascular Institute Workshop, recent
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developments in the field of RIC were discussed with a
focus on new insights into the underlying mechanisms, the
diversity of non-cardiac protection, new clinical applica-
tions, and large outcome studies. The scientific advances
made in this field of research highlight the journey that RIC
has made from being an intriguing experimental observa-
tion to a clinical application with patient benefit.
Keywords Ischemia  Organ protection  Remote
ischemic conditioning  Reperfusion
Introduction
Ischemic heart disease (IHD) maintains its unrelenting grip
as the leading cause of death and disability worldwide.
Therefore, novel therapeutic strategies are required to
protect the heart against acute ischemia/reperfusion injury
(IRI) to attenuate cardiomyocyte death, preserve cardiac
function, prevent the onset of heart failure, and improve
clinical outcomes in patients with IHD. In 1993, Przyklenk
and colleagues [76] first demonstrated that applying cycles
of brief ischemia and reperfusion to myocardium in the
circumflex coronary artery territory protected remote virgin
myocardium in the left anterior descending coronary artery
territory. This intriguing observation extended the concept
of direct ischemic preconditioning of the heart, initially
described by Murry et al. [71] in 1986, to protect the heart
at a distance or ‘remote ischemic conditioning’ (RIC). Over
the last 20 years, the concept of RIC has evolved from
being an experimental observation, whose underlying
mechanisms continue to elude investigators, to a clinical
application which offers the therapeutic potential to benefit
patients with IHD (reviewed in [10, 31, 38–40]).
Yet many questions remain unanswered and several
issues remain unresolved. The 8th Biennial Hatter Car-
diovascular Institute Workshop, which was held at the
University College London Hatter Cardiovascular Institute
in the UK in April 2014, convened over 50 international
investigators to discuss some of these questions and issues
surrounding RIC. The focus of the Hatter Cardiovascular
Institute (HCI) Workshop was on RIC induced by brief
limb ischemia and reperfusion as this method of RIC has
been the most clinically applicable strategy. The discussed
topics included the mechanisms underlying RIC, non-car-
diac RIC protection, the clinical application of RIC, and
the potential for RIC to improve clinical outcomes.
New insights into the mechanisms underlying RIC: why
does it still elude us?
Despite intensive investigation over the last 20 years, the
mechanisms underlying RIC remain unclear. The current
paradigm divides the mechanistic pathway underlying RIC
into three inter-related components as follows [10, 31, 38,
40]:
(1) Remote organ or tissue: in response to the RIC
stimulus autacoids generated within the remote organ or
tissue activate a local afferent neural pathway [62, 86, 95].
(2) The connecting pathway: the mechanistic pathway
conveying the protective signal from the remote organ or
tissue to the target organ or tissue has not been fully
resolved. It has been shown to be dependent on both a
humoral pathway (i.e. comprising blood-borne protective
factor(s)) and a neural pathway to the remote organ or
tissue.
(3) Target organ or tissue: the blood-borne protective
factor(s) appear(s) to recruit intracellular signaling path-
ways from the remote organ or tissue which are known to
mediate the protective effects induced by direct ischemic
preconditioning and postconditioning.
What is the nature of the neural pathway underlying RIC?
Experimental and clinical studies have demonstrated that
RIC protection is dependent on an intact neural pathway to
the remote organ or tissue with local resection of the neural
pathway abolishing RIC protection [27, 63]. However, the
actual nature of the neural pathway in terms of its afferent,
central, and efferent components remains unclear. The
current paradigm has proposed that in response to the RIC
stimulus, autacoids such as adenosine [23, 62, 86] and
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bradykinin [95] are produced in the remote organ or tissue
resulting in the nitric oxide-dependant stimulation of local
afferent sensory nerves. At the HCI Workshop, Kharbanda
(Oxford, UK) presented unpublished human data investi-
gating whether adenosine provides the ‘trigger’ for the
limb RIC stimulus in IHD patients undergoing coronary
angiography. Utilizing the human forearm model, they
found that local arterial infusion of caffeine (a non-specific
adenosine receptor antagonist) into the trigger arm blocked
the beneficial effects of RIC on preventing ischemia-
induced endothelial dysfunction, and inhibited the pro-
duction of a cardioprotective plasma dialysate. Further-
more, the administration of an arterial infusion of
adenosine into the femoral artery resulted in the production
of a cardioprotective plasma dialysate in patients under-
going coronary angiography, confirming the findings in
experimental animal studies that adenosine acted as a
‘trigger’ for limb RIC [86]. Most recent experimental data
have suggested that the sensory arm of the neural pathway
leading from the remote organ or tissue may be recruited
by the activation of transient receptor potential vanilloid
(TRPV) receptors, which are prevalent in unmyelinated
small diameter (Ad & C) sensory fibers [6, 47, 81].
Experimental studies have demonstrated that the activation
of these fibers by topical capsaicin or nociceptive stimuli
can recapitulate limb RIC cardioprotection [6, 47, 81].
However, the neural components of the pathway
downstream of this sensory afferent neural pathway in the
remote organ or tissue remain unclear. Jones et al. [47]
found that cardioprotection elicited by peripheral noci-
ception was blocked by spinal transection at T7 but not C7,
suggesting that direct stimulation of cardiac nerves may be
responsible for conveying the cardioprotective signal to the
heart. In contrast to this study, and using an elegant
experimental optogenetic approach, Gourine (London, UK)
[64] has recently shown that the activity of the brainstem
vagal preganglionic neuronsis required to mediate the
protective effect of limb RIC on the heart, with their
activation inducing powerful cardioprotection and their
inhibition abrogating the beneficial effects of RIC [64]. To
study the role of the efferent vagal pathway to limb RIC
cardioprotection, Donato et al. [22] showed that resection
of the vagal nerve and atropine abolished the MI-limiting
effects of limb RIC in the rabbit heart and stimulation of
the vagal nerve recapitulated limb RIC cardioprotection.
However, dependency of limb RIC cardioprotection on the
parasympathetic nervous system appears to preclude a role
for a blood-borne cardioprotective factor.
Whether an efferent neural pathway is actually required
to convey the cardioprotective signal to the heart or whether
this is simply mediated by a blood-borne cardioprotective
factor to the heart is not fully resolved. Kingma et al. [52]
reported that neither the ganglionic blocker
(hexamethonium) nor cardiac denervation abolished renal
RIC protection of the canine heart. Similarly, Rassaf et al.
[79] found that MI size reduction by limb RIC in the murine
heart persisted despite femoral nerve resection (although
the sciatic nerve was not resected in this model). Clearly,
further studies are required to elucidate the details of the
neural pathway underlying limb RIC cardioprotection.
What is the identity of the blood-borne cardioprotective
factor?
The earliest experimental evidence for a blood-borne car-
dioprotective factor released by RIC was provided in 1999
by Dickson et al. [21], who demonstrated that the cardio-
protective effect elicited by ischemic preconditioning of
the heart and kidney in one rabbit could be transferred via
whole blood transfusion to a non-preconditioned rabbit.
Since then, a number of experimental studies have
attempted to identify the blood-borne cardioprotective
factor(s), resulting in a number of candidate factors being
proposed including calcitonin gene-related peptide [87],
opioids [73], endogenous cannabinoids [30], and hypoxia-
inducible factor-1a (HIF-1a) [50].
Although the actual identity of the factor remains
unclear, biochemical studies have suggested that the factor
may be a peptide less than 30 kDa in size [58, 84]. Using
proteomic analysis of plasma following RIC to identify the
blood-borne cardioprotective factor(s) has been challeng-
ing. At the HCI Workshop, a number of novel candidates
for the blood-borne cardioprotective factor(s) of RIC were
proposed, each with varying degrees of experimental evi-
dence: including (1) stromal-derived factor-1a or SDF-1a
(S Davidson, London, UK) [19]; (2) exosomes (Giricz and
Ferdinandy, Budapest, Hungary) [28]; nitrite (Heusch,
Essen, Germany) [78, 79]; (3) microRNA-144 (Redington,
Toronto, Canada) [60]; (4) HIF-1a (Prunier, Anger,
France) [48]; and (5) Apolipoprotein a-I (Prunier) [41]. Of
these, the most promising candidates for the blood-borne
cardioprotective factor of RIC in terms of the available
experimental evidence are probably SDF-1a, nitrite, and
microRNA-144, as in these three cases limb RIC was
demonstrated to elevate levels of the putative factor in the
plasma, and blocking the factor also abolished the cardio-
protective effect of RIC. However, these studies have
failed to provide direct evidence that the factor secreted
into the blood was actually responsible for the cardiopro-
tective effect. Furthermore, it is important to note that none
of these studies actually provided evidence that the pro-
duction of the putative factor in response to RIC was
dependent on an intact neural pathway to the limb, an
important omission given that the blood-borne cardiopro-
tective factor has been shown to be released downstream of
the neural pathway (see next section).
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How do the neural and humoral pathways interact
to mediate RIC?
The neural and humoral pathways underlying limb RIC
have been known to interact to mediate the protective
effect, but the actual nature of this relationship has not been
clear until very recently (see Fig. 1 for a hypothetical
scheme). Emerging studies from Redington’s and Botker’s
research groups have begun to unravel the interplay
between these two pathways in the setting of limb RIC.
The major advance in this regard, has been facilitated by
their use of an experimental model in which cardiopro-
tective plasma dialysate harvested from animals or humans
treated with limb RIC is demonstrated to reduce MI size in
naı¨ve animal hearts. Using this experimental model, they
have been able to provide evidence showing that the blood-
borne cardioprotective factor is produced downstream of
the neural pathway. Redington’s group has shown that the
cardioprotective plasma dialysate can be produced in ani-
mals and human volunteers in response to sensory neural
stimulation of the limb using a number of different
approaches including direct nerve stimulation [81], trans-
cutaneous electrical nerve stimulation [68], electro-acu-
puncture [80] and even topical capsaicin [6, 81]. Botker’s
group has demonstrated that diabetic patients with a
peripheral sensory neuropathy in their upper limbs do not
Fig. 1 Connecting the limb to the heart in RIC. This figure shows the
potential interplay between the neural pathway (green solid lines) and
humoral pathway (broken red lines) in mediating RIC cardioprotec-
tion. Cycles of brief upper limb ischemia/reperfusion induced by
inflation/deflation of a cuff placed on the upper arm produce the local
release of autacoids, which then activate local sensory afferent
neurons. One experimental study has shown the involvement of the
neuronal activity in the brainstem dorsal motor vagal nucleus
(DMVN) in RIC cardioprotection—this provides parasympathetic
innervation of the left ventricle and other internal organs. A
circulating blood-borne cardioprotective factor(s) is produced in
response to the RIC stimulus downstream of the local sensory afferent
neurons in the upper limb, but the actual source for its release is not
currently known. Potential sites of release of the cardioprotective
factor(s) include: (1) from the conditioned limb itself, (2) from the
central nervous system (brainstem), (3) from pre-/post-ganglionic
parasympathetic nerve endings within the heart (broken green lines);
and (4) from a non-conditioned remote organ/tissue receiving
parasympathetic innervation
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produce the cardioprotective plasma dialysate in response
to limb RIC, when compared to diabetic patients with no
sensory neuropathy [46]. Therefore, the combined evidence
suggests that the blood-borne cardioprotective factor is
most likely produced downstream of the neural pathway.
But of course questions remain as to where along the neural
pathway is the cardioprotective factor released into the
blood stream, and which cell is actually responsible for its
release.
Novel mediators of RIC cardioprotection in the heart
The current paradigm suggests that the cardioprotective
signal initiated by limb RIC recruits signal transduction
pathways (such as PI3K-Akt) in the target organ or tissue,
which are known to be mediators of direct ischemic pre-
conditioning and postconditioning [36, 37, 61]. In the HCI
Workshop, data were presented implicating two novel
mediators of limb RIC cardioprotection including aldehyde
dehydrogenase-2 (ALDH-2) and phospho-myozenin-2.
Kharbanda presented recent data showing in an animal MI
model and human volunteers that the protective effect of
limb RIC was abolished in the presence of an ALDH-2
inhibitor [13]. Interestingly, in support of a role for ALDH-
2, human volunteers with a Glu504Lys polymorphism in
ALDH-2 were found to be resistant to RIC protection
against ischemia-induced endothelial dysfunction [13].
Further study is required to determine where in the
mechanistic pathway ALDH-2 plays its mediatory role and
to identify its downstream effectors. Suleiman (Bristol,
UK) presented recent data investigating cardiac phospho-
proteomics in the setting of limb RIC, demonstrating the
phosphorylation of the cardiac sarcomeric protein, phos-
pho-myozenin-2. These findings suggest that RIC may
have functional effects on myocardial contractile function
[1]. The importance of this to the cardioprotective effect
induced by RIC remains to be investigated.
Protecting non-cardiac organs by limb RIC
The key advantage of limb RIC as a therapeutic strategy is
that it offers multi-organ protection against acute IRI. As
such limb, RIC has been shown to be beneficial in a
number of non-cardiac organs including the brain, the
kidney, and the liver. In the HCI Workshop, a number of
novel applications of RIC in non-cardiac protection were
discussed.
Neuroprotection by RIC
It has been well established in the neuroprotection exper-
imental literature that RIC can limit cerebral infarct size
following an acute ischemic stroke [29]. At the HCI
Workshop, Botker presented a recent clinical study inves-
tigating the effect of limb RIC in patients thrombolysed for
an acute ischemic stroke—no clear benefit was found in
terms of cerebral infarct size and functional recovery [44].
However, a small clinical study by Meng et al. [67] com-
prising 63 patients with prior stroke or transient ischemic
accident demonstrated that RIC repeated twice daily for
300 days was able to reduce the recurrence of stroke and to
improve functional recovery.
Cerebral IRI arising from perinatal hypoxic-ischemia,
results in significant neonatal morbidity and long-term
neurological impairment [59], despite the adoption of
hypothermic neuroprotection in the developed world [5]. In
this regard, N Robertson (London, UK) presented a recent
study investigating the effect of limb RIC applied at the
onset of reperfusion using a porcine model of neonatal
cerebral hypoxia–ischemia. Limb RIC preserved cerebral
white matter metabolism on magnetic resonance spectros-
copy and reduced white matter cell death following tran-
sient global cerebral hypoxia–ischemia, suggesting that
RIC may have therapeutic potential as a neuroprotective
strategy for mitigating brain injury and improving out-
comes in babies with birth asphyxia. This may have
important implications in low resource countries where
limb RIC could be used as a simple and low-cost neuro-
protective intervention.
Renoprotection by RIC
Limb RIC has been investigated as a renoprotective strat-
egy in several different clinical settings in which there is a
risk of acute renal IRI [26]. In patients undergoing either
cardiac bypass or major vascular surgery, acute renal IRI is
a major determinant of acute kidney injury (AKI), a
complication which occurs in 20–30 % of patients and
which is associated with worse clinical outcomes. Several
clinical studies have investigated a potential protective role
of RIC on AKI in these surgical settings, but the results
have been inconclusive [11, 77, 91]. The results of the
large multicentre ERICCA [33] and RIPHeart [69] trials
which are also investigating the effect of limb RIC on AKI
should hopefully provide a definitive answer as to whether
limb RIC is renoprotective in the setting of cardiac surgery.
Contrast-induced AKI (CI-AKI) is a significant cause of
renal impairment in IHD patients undergoing coronary
angiography and interventions, and one component of the
injury is due to acute renal ischemic injury, and therefore a
potential target for limb RIC [88]. Er et al. [24] have
investigated in the Renal Protection Trial the effect of limb
RIC on the incidence of CI-AKI in 100 high-risk patients
undergoing coronary angiography and interventions who
were pre-treated with intravenous normal saline and oral
N-acetylcysteine—limb RIC reduced the incidence of CI-
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AKI from 40 to 12 %. The ERIC-CIN study in the UK is
currently investigating whether the renoprotective effect of
limb RIC is still present in 362 patients pre-treated with
sodium bicarbonate prior to coronary angiography and
procedures [7]. At the HCI Workshop, Crimi (Pavia, Italy)
presented data investigating the effect of limb RIC on CI-
AKI in STEMI patients treated by primary percutaneous
coronary intervention (PPCI). In the original study, his
team had already demonstrated a cardioprotective effect of
limb RIC in this patient group with reduced enzymatic
myocardial infarct size, and in this post hoc sub-group
analysis they found that compared to control, limb RIC
appeared to reduce the incidence of AKI in those STEMI
patients with impaired renal function prior to PPCI [14,
15]. Finally, The EUROpean and Chinese cardiac and renal
Remote Ischemic Preconditioning Study (EURO-CRIPS)
trial will investigate both the renal and myocardial pro-
tective effects of limb RIC against CI-AKI and peri-pro-
cedural myocardial injury in 1,110 patients undergoing
elective PCI, respectively [70].
Acute renal IRI sustained during pediatric renal transplan-
tation is a critical determinant of graft function and clinical
outcomes. MacAllister (London, UK) presented unpublished
data from the REnal Protection Against Ischaemia–Reperfu-
sion in transplantation (REPAIRISRCTN30083294) trial, a
randomized double-blinded placebo-controlled trial of 400
living-donor renal transplant patients investigating the effect
of limb RIC on renal graft function. He found that in those
patients in whom limb RIC was administered to the donor and
recipient, the estimated GFR at 6 months post-transplantation
was increased compared to control, suggesting limb RIC to be
a potential therapeutic strategy for preserving renal graft
function post-transplantation.
Liver protection by RIC
B Davidson (London, UK) has been investigating in pre-
clinical studies the protective effect and mechanisms under-
lying hepatic protection against acute IRI induced by limb
RIC [2, 3, 49]. In the HCI Workshop, data were presented
translating this therapeutic approach into the clinical setting,
with a small study of 16 patients showing that limb RIC
reduced the release of liver enzymes following liver resection
surgery (ClinicalTrials.gov Identifier: NCT007965880). The
ongoing Remote Ischaemic PreCOnditioning in Liver
Transplant (RIPCOLT) study is currently investigating the
efficacy of limb RIC in 40 liver transplant patients on liver
protection and graft and patient survival.
Novel clinical applications of RIC to protect the heart
The first clinical study to demonstrate the clinical appli-
cation of limb RIC was by Redington and colleagues in
2006 who reported beneficial effects with this intervention
in children undergoing corrective cardiac surgery [12]
(Table 1). Since then limb RIC has been shown to attenuate
acute myocardial IRI in a number of different clinical
settings including cardiac bypass surgery [35, 89], major
vascular surgery [4], elective PCI [43], and more recently
STEMI patients treated by PPCI [8, 15, 75, 82, 94]
(Table 1). In the HCI Workshop, Walsh (Galway, Ireland)
presented details of the forthcoming Preconditioning
Shields Against Vascular Events in Surgery (SAVES) trial
(ClinicalTrials.gov Identifier:NCT01691911) which will
investigate the effect of limb RIC on peri-operative myo-
cardial injury in 400 patients undergoing major vascular
surgery.
In the HCI Workshop, several novel applications of limb
RIC for protecting the heart were discussed. Garcia-Dorado
(Barcelona, Spain) presented unpublished data demon-
strating the synergistic effect of limb RIC with either ex-
enatide or glucose–insulin–potassium therapy administered
at the time of reperfusion in terms of MI reduction in an
in vivo porcine model of acute IRI. The concept of com-
bining therapies which have a potential synergistic car-
dioprotective effect has not yet been tested in the clinical
setting and it may actually be a more effective therapeutic
strategy than using a mono therapy approach.
Limb RIC has already been shown to reduce MI size in
STEMI patients treated by PPCI (Table 1). However, in
developing countries in which PPCI is not readily avail-
able, STEMI patients are still reperfused by thrombolytic
therapy—whether RIC is cardioprotective in this setting is
not known. In the HCI Workshop, Hausenloy & Yellon
(London, UK) presented unpublished results of the ERIC-
LYSIS study (ClinicalTrials.gov Identifier:NCT02197117),
a 519 STEMI patient multi-center clinical trial in the Island
of Mauritius, showing that limb RIC initiated on arrival at
the hospital prior to thrombolysis, reduced serum enzy-
matic MI size by 17 %. A large clinical outcome study is
now planned to investigate whether limb RIC can reduce
cardiac death and hospitalization for heart failure at
12 months in thrombolysed STEMI patients (the ERIC-
LYSIS 2 trial).
The effect of RIC on exercise capacity in patients with
heart failure has recently been investigated by Redington
and colleagues [66]. Although they found no improvement
in oxygen consumption with RIC when compared to sham,
they did observe that plasma dialysate from both sham and
RIC patients reduced murine MI size compared to plasma
dialysate from historical healthy controls, suggesting heart
failure patients, irrespective of RIC or sham intervention,
may be subjected to a permanent chronic preconditioning
stimulus per se [66].
Most previous clinical studies have investigated the
cardioprotective effects of a single limb RIC stimulus
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targeted against an acute episode of IRI. Whether repeated
episodes of limb RIC, applied as a chronic therapeutic
intervention, are also beneficial has been recently investi-
gated. An experimental study has reported that repeating
RIC daily for 28 days prevented adverse post-MI left ven-
tricle (LV) remodeling in the rat heart [93]. The mechanism
for this beneficial effect is not clear but may relate to RIC-
mediated attenuation of the immune, inflammatory and
apoptotic response to MI. The concept of daily RIC is
already being tested in the clinical setting in several clinical
studies. Vanezis (Leicester, UK) presented details of the
ongoing Daily REmote Ischaemic Conditioning following
Acute Myocardial Infarction (DREAM, ClinicalTrials.gov
Identifier: NCT01664611) trial in the UK, which is
exploring the effect of daily RIC initiated after PPCI and
continued for 4 weeks in 72 STEMI patients presenting
with impaired LV ejection fraction (EF \ 45 %)—primary
endpoint of [5 % improvement in LVEF at 4 weeks post-
MI. In Canada, the Chronic Remote Ischemic Conditioning
to Modify Post-MI Remodeling (CRIC-RCT;ClinicalTri-
als.gov Identifier:NCT01817114) trial in Canada is testing
the effect of repeating RIC daily for 28 days on the change
from baseline in LV end diastolic volume at 28 days by
cardiac MRI in 82 STEMI patients treated by PPCI. Finally,
in the CONDI-HF study (ClinicalTrials.gov Identi-
fier:NCT02248441), Botker and colleagues are currently
investigating the effect of daily RIC in 50 chronic heart
failure patients using LV ejection fraction assessed by
cardiac MRI as the primary endpoint.
Chronic renal failure patients treated by haemodialysis
have a significantly increased risk of cardiovascular mor-
bidity and mortality. These patients experience repeated
bouts of acute myocardial ischemia and stunning every
time they have haemodialysis leading to chronic impair-
ment of LV systolic function, resulting in de novo and
recurrent heart failure with a 2-year mortality rate of 51 %
[9]. At the HCI Workshop, McIntyre (Ontario, Canada)
presented data investigating the potential cardioprotective
benefit of RIC in this patient group. They found that limb
RIC administered prior to haemodialysis prevented ST-
segment depression and attenuated myocardial stunning
compared to control, suggesting a potential cardioprotec-
tive effect of RIC on myocardial function in patients with
chronic kidney failure [16]. Interestingly, it has been
observed that haemodialysis patients with arteriovenous
fistula experience fewer complications and lower mortality
when compared to patients with alternative forms of vas-
cular access [74]. Whether the beneficial effect of having
arteriovenous fistula is inadvertently limb preconditioning
the patient by inducing episodes of limb ischemia was
raised as a possibility by McIntyre [54].
The majority of published clinical studies investigating
the efficacy of limb RIC have used a manual blood pressureT
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cuff to apply the RIC protocol. However, there is currently
an automated cuff device available for delivering the limb
RIC protocol. Ganske (CellAegis, Toronto, Cananda) pre-
sented the AutoRIC device which is able to deliver a
standard limb RIC protocol (four 5 min cycles of upper
arm cuff inflation/deflation) with a single push of a button,
facilitating the delivery of limb RIC in clinical trials,
especially where it is proposed as a potential chronic
therapy.
Why the neutral clinical RIC studies?
A number of clinical studies have failed to find any ben-
eficial effects of limb RIC in patients undergoing PCI [45],
CABG [51] and vascular surgery [92]; these include some
large clinical trials conducted in pediatric [65] and adult
cardiac surgery [42, 77]. Recent meta-analyses have for the
most part reported beneficial effects with limb RIC in terms
of reducing myocardial injury in the settings of cardiac
bypass surgery [17] and PCI [18].
The one setting in which the effect of RIC has been
predominantly positive is in STEMI patients treated by
PPCI with five proof-of-concept studies reporting cardio-
protective effects with limb RIC applied at the time of
PPCI [8, 15, 75, 82, 94]. Several review articles have been
published analyzing the potential reasons underlying the
failure to translate cardioprotection into the clinical setting
[32, 34, 72, 83]. At the HCI Workshop, some of these
factors were discussed—they relate to patient selection, the
RIC stimulus (the optimal stimulus remains unclear), the
blinding of the RIC stimulus, the study design and choice
of measured endpoints, confounding factors (such as age,
diabetes, hyperlipidemia which may interfere with cardio-
protection), and concomitant medications (such as volatile
anesthetics, nitrates, statins which also interfere with car-
dioprotection) [25, 32, 34, 72]. Heusch presented a retro-
spective analysis of the Essen RIC trial on CABG patients
[90], and identified anesthesia [55, 56], age, duration of
index ischemia and sulphonylurea treatment of diabetics
[57], but not use of nitroglycerine during surgery [53] as
potential confounders.
Improving clinical outcomes with limb RIC—Will it
change clinical practice?
Most of the published clinical studies have established that
limb RIC can limit myocardial injury in PCI, CABG and
STEMI patients (Table 1). In the HCI Workshop, Hau-
senloy presented the results of a clinical study reporting
that limb RIC could reduce the incidence of post-operative
atrial fibrillation, acute kidney injury, and it could shorten
ITU stay in patients undergoing CABG plus or minus valve
surgery, suggesting some benefit on short-term clinical
outcomes post-surgery [11]. Whether limb RIC can actu-
ally improve long-term clinical outcomes in these clinical
settings remains unknown. In this regard, Botker, Heusch,
and Dutka (Cambridge, UK) presented data at the HCI
Workshop suggesting that limb RIC may improve long-
term clinical endpoints in STEMI [85], CABG surgery [90]
and elective PCI [20] patients, respectively, although none
of these studies were prospectively designed or powered to
investigate the effect of limb RIC on long-term clinical
outcomes (Table 1). Meybohm and Hausenloy presented
the forthcoming RIPHEART [69] and ERICCA [33] trials,
respectively, which have been powered to investigate
whether limb RIC can improve clinical outcomes at their
primary endpoint in the setting of cardiac bypass surgery
(Table 1). Furthermore, a research collaboration between
the UK (Hausenloy) and Denmark (Botker) will investigate
the effect of limb RIC on improving clinical outcomes in
STEMI patients treated by PPCI in the RIC-PPCI and
CONDI2 trials (Table 1). Depending on the results of these
large multi-center clinical outcome studies, there is the
potential for limb RIC to change clinical practice.
Summary and Conclusions
The 8th Biennial Hatter Cardiovascular Workshop pro-
vided a great opportunity to discuss recent developments in
the research field of limb RIC including: (1) new insights
into the mechanisms underlying limb RIC; (2) expansion of
non-cardiac organ protection; (3) potentially novel clinical
applications of limb RIC; and (4) an update of recently
published and future clinical outcomes studies. Huge
advances have clearly been made over the last few years
regarding the mechanisms underlying limb RIC and its
potential in the clinical setting, thereby enabling limb RIC
to make the journey from an intriguing experimental
observation to a clinical application for patient benefit.
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